DDX5, in contrast, is generally described to have a consistently oncogenic effect through its regulation of the Wnt, Notch, mammalian target of rapamycin (mTOR), and forkhead box O3a (FOXO3a) pathways all involved in cancer progression [180, 212, 213, 214, 215]. Here, DDX5 is linked to cancer.